Indole-3-propionic acid protein binding for blood-brain barrier transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for late-onset neurodegenerative and cardiovascular diseases, such as Huntington's Disease, Alzheimer's, and stroke, lack effective therapies to delay onset or slow progression, and existing monitoring methods are invasive and costly, with a need for non-invasive biomarkers to assess disease progression and therapeutic efficacy.
Innovation Solution
The use of indole-3-propionic acid (IPA) as a therapeutic agent, bound to proteins, to protect against protein aggregation and oxidative damage, combined with non-invasive monitoring techniques using metabolomic profiling to assess IPA levels in urine and blood, allowing for early intervention and risk reduction by modifying the gut microbiome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IPA is used as a therapeutic agent to protect against protein aggregation and oxidative damage, then disease progression is slowed and neuronal protection is improved, but the complexity of delivering sufficient IPA across the blood-brain barrier increases
Solution Approach 1:
The patent employs plasma proteins (albumin and immunoglobulins) as intermediary carriers to transport IPA across the blood-brain barrier. IPA binds strongly to these proteins in plasma, and the protein-IPA complex facilitates transport into the brain, solving the delivery problem without requiring complex synthetic delivery systems
Solution Approach 2:
The patent utilizes the body's existing plasma protein transport system to deliver IPA to the brain. The natural binding affinity between IPA and plasma proteins creates a self-service delivery mechanism where the body's own circulatory and protein transport systems perform the delivery function, eliminating the need for external complex delivery devices
2Ease of operation
If non-invasive monitoring methods are used to assess IPA levels, then patient comfort and accessibility are improved, but the precision and reliability of measurement may be compromised
Solution Approach 1:
The patent measures IPA levels in easily accessible body fluids (urine, plasma, CSF) as proxies or copies of brain IPA levels. Since IPA crosses the blood-brain barrier and reaches the CNS, measuring its concentration in peripheral fluids provides an accurate indirect assessment of brain IPA levels without requiring invasive brain sampling
Solution Approach 2:
The patent replaces invasive mechanical sampling procedures (such as brain tissue biopsy) with non-invasive fluid collection methods (urine collection, blood draw). This substitution maintains measurement capability while eliminating the harmful mechanical intrusion into the patient's body
3Reliability
If IPA levels are increased through supplementation and gut microbiome modification, then disease risk is reduced and therapeutic efficacy is improved, but the complexity of modifying the gut microbiome increases
Solution Approach 1:
The patent targets multiple sources of IPA production simultaneously: dietary supplementation, gut microbiome production, and plasma protein binding. By activating multiple pathways, the system achieves robust IPA elevation through various mechanisms working together, where failure of one pathway can be compensated by others
Solution Approach 2:
The patent modifies the chemical environment of the gut by changing pH, nutrient availability, and microbial substrate composition to favor IPA-producing bacteria. By altering these physiological parameters, the existing gut microbiome is redirected to produce more IPA without requiring complete microbiome replacement or complex genetic engineering
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IPA supplementation and gut microbiome modification can delay disease onset, improve quality of life, and reduce the risk of neurodegenerative diseases, while non-invasive monitoring enables cost-effective and efficient assessment of therapeutic outcomes.
Implementation Method 1
Current understanding is that IPA serves as an antioxidant whose intermediate indoxyl positive free radical, unlike such compounds as tocopherols and carotenes has no pro oxidant intermediates
Implementation Method 2
We have shown that in plasma IPA is strongly bound to plasma proteins both albumin and imunoglobulins with normal plasma levels of ca. 200 ng/ml and free levels of ca. 0.1 ng/ml
Implementation Method 3
We have shown that on free radical attack the intermediate positive ion free radical binds to protein as a kynuric acid moiety
Implementation Method 4
in vitro has been shown to suppress protein aggregation and suggested as a therapeutic for Alzheimer's Disease
Implementation Method 5
We have shown that in plasma IPA is strongly bound to plasma proteins both albumin and imunoglobulins... We have shown that IPA produced in the gut enters the plasma and crosses the BBB and is found in brain and CSF
Data Source
Figure 1A~2B
Figure 3~4
Figure 5~6
AI summary
lndole-3-propionic acid as a marker and for treatment for Huntington Disease. An exemplary pharmaceutical composition for treating or preventing neurodegenerative 3 disease, hypertension, stroke, ischemic heart disease or head injury in an animal, or for delaying or ameliorating the effects of said disease or injury in an animal suffering from same may comprise indole-3-propionic acid or a salt or ester or protein 6 complex or inorganically bound preparation thereof and a pharmaceutically acceptable carrier therefor.